Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Michele Volansky

Physician Assistant Atlanta, GA Physician Assistant

NPI 1003944778 CMS profile 11030605

77 Collier Rd Nw, Suite 2080, Atlanta, GA 30309

Open in the dashboard

General payments

$9,376

421 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michele Volansky of Atlanta, GA is reported in the CMS Open Payments database as having received $9,376 across 421 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,750 77
2024 General $1,781 81
2023 General $3,234 105
2022 General $1,641 90
2021 General $970 68

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michele Volansky
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Michele Volansky were reported at $1,750. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Michele Volansky Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $970 $132 $37–$438 $132
2022 $1,641 $155 $48–$522 $149
2023 $3,234 $167 $52–$557 $160
2024 $1,781 $178 $55–$600 $164
2025 $1,750 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,959 148 payments
  2. AstraZeneca Pharmaceuticals LP $1,721 14 payments
  3. Amgen Inc. $1,454 91 payments
  4. Genzyme Corporation $803 21 payments
  5. Janssen Biotech, Inc. $749 23 payments
  6. UCB, Inc. $675 36 payments
  7. Novartis Pharmaceuticals Corporation $505 30 payments
  8. GlaxoSmithKline, LLC. $261 12 payments
  9. ANI Pharmaceuticals, Inc. $220 1 payment
  10. Radius Health, Inc. $150 6 payments
  11. Other $878 39 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $7,641 414 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,500 3 payments
  3. Education $235 4 payments
Products named General payments · program years 2021–2025
  1. SAPHNELO $1,721 14 payments
  2. RINVOQ $1,484 113 payments
  3. TREMFYA $660 20 payments
  4. Otezla $642 40 payments
  5. KEVZARA $638 11 payments
  6. Enbrel Inflammation $610 37 payments
  7. Enbrel Inflammation $436 34 payments
  8. SIMPONI ARIA $361 11 payments
  9. Cimzia $350 17 payments
  10. SKYRIZI $348 24 payments
  11. Other $3,123 150 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

476

Median for Physician Assistant: 241

Drug cost

$463,650

Median for Physician Assistant: $4,110

Branded share of claims

35.5%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira(Cf) Adalimumab Brand 17 $138,039
Enbrel Sureclick Etanercept Brand 17 $135,035
Rinvoq Upadacitinib Brand 15 $106,834
Xeljanz Tofacitinib Citrate Brand 14 $76,768
Hydroxychloroquine Sulfate Generic 61 $2,860
Methotrexate Methotrexate Sodium Brand 95 $1,822
Leflunomide Generic 17 $733
Allopurinol Generic 32 $331
Methylprednisolone Generic 53 $261
Prednisone Generic 58 $251

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
PURIFIED CORTROPHIN GEL
  • ANI Pharmaceuticals, Inc. $220
$220 — —
KEVZARA
  • GENZYME CORPORATION $210
$210 — —
RINVOQ
  • AbbVie, Inc. $204
$204 15 —
Enbrel
  • Amgen Inc. $186
$186 17 —
TREMFYA
  • Janssen Biotech, Inc. $147
$147 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

421 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record